Sionna Therapeutics, Inc./$SION
1D1W1MYTD1Y5YMAX
Capital at risk
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
- Ticker
- $SION
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 59
- Headquarters
- Waltham, United States
- Website
- www.sionnatx.com
SION Metrics
BasicAdvanced
$325M
-
-$2.17
-
-
Price and volume
Market cap
$325M
52-week high
$54.97
52-week low
$4.01
Average daily volume
3.6M
Financial strength
Current ratio
20.045
Quick ratio
19.573
Long term debt to equity
0.025
Total debt to equity
0.03
Profitability
EBITDA (TTM)
-108.836
Management effectiveness
Return on assets (TTM)
-21.54%
Return on equity (TTM)
-32.34%
Valuation
Price to book
1.22
Price to tangible book (TTM)
1.22
Price to free cash flow (TTM)
-4.232
Free cash flow yield (TTM)
-23.63%
Free cash flow per share (TTM)
-1.697
Growth
Earnings per share change (TTM)
-42.82%
Bulls say / Bears say
Completion of enrollment in the Phase 2a PreciSION CF trial of first-in-class NBD1 stabilizer SION-719 as an add-on to Trikafta reduces development risk ahead of a topline readout in summer 2026 (GlobeNewswire).
Ongoing Phase 1 dual-combination trial evaluating SION-451 with complementary CFTR modulators SION-2222 and SION-109 broadens Sionna’s pipeline with multiple mid-2026 data catalysts (GlobeNewswire).
Strong balance sheet with $268.3 million in cash and cash equivalents as of June 30, 2026 provides funding into 2028 to support clinical progress through key data readouts (GlobeNewswire).
Net loss widened to $29.9 million in Q2 2026 from $18.1 million a year earlier, driven by increased R&D and G&A spend, heightening the risk of accelerated cash burn and potential dilution (GlobeNewswire).
Sionna’s business is substantially dependent on the success of early-stage NBD1 stabilizers SION-719 and SION-451, with no late-stage assets to mitigate binary trial outcomes this summer (SEC 10-Q).
Intense competition from Vertex’s established CFTR modulators and emerging gene-editing and mRNA therapies could limit the commercial uptake of Sionna’s candidates even if approved (SEC 10-Q).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Upcoming events
Funds containing SION
AllUSDGBPEUR
Fund name | Fund size | $SION weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.